|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2011-5-3
|
|
pubmed:abstractText |
To evaluate the efficacy and safety of ezogabine (United States adopted name)/retigabine (international nonproprietary name) (EZG[RTG]) 1,200 mg/day as adjunctive treatment in adults with drug-resistant epilepsy with partial-onset seizures with or without secondary generalization.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1526-632X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
3
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1555-63
|
|
pubmed:meshHeading |
pubmed-meshheading:21451152-Adolescent,
pubmed-meshheading:21451152-Adult,
pubmed-meshheading:21451152-Aged,
pubmed-meshheading:21451152-Anticonvulsants,
pubmed-meshheading:21451152-Carbamates,
pubmed-meshheading:21451152-Dose-Response Relationship, Drug,
pubmed-meshheading:21451152-Double-Blind Method,
pubmed-meshheading:21451152-Drug Administration Schedule,
pubmed-meshheading:21451152-Epilepsies, Partial,
pubmed-meshheading:21451152-Female,
pubmed-meshheading:21451152-Humans,
pubmed-meshheading:21451152-Male,
pubmed-meshheading:21451152-Middle Aged,
pubmed-meshheading:21451152-Phenylenediamines,
pubmed-meshheading:21451152-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.
|
|
pubmed:affiliation |
NYU Comprehensive Epilepsy Center, 223 East 34th Street, New York, NY 10016, USA. Jacqueline.french@nyumc.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
